معرفی
Paul Jennings is a Full Professor and Chair of Molecular and Computational Toxicology at the Vrije Universiteit Amsterdam (VU), Netherlands. He holds dual appointments in the Faculty of Science (Chemistry and Pharmaceutical Sciences Department) and AIMMS. His research focuses on advancing in vitro toxicology models, particularly for renal and hepatic systems, integrating omics technologies and computational approaches to understand chemical toxicity mechanisms. Jennings has pioneered the use of induced pluripotent stem cells (iPSCs) for developing patient-specific models to study nephrotoxicity and stress response pathways such as Nrf2, p53, and HIF-1α. He has led major EU projects like EUToxRisk and OpenRiskNet, advancing animal-free testing strategies aligned with Adverse Outcome Pathways (AOPs).
Education: BSc (Pharmacology, UCD Dublin), PhD (Nephrotoxicity Testing, UCD Dublin), Habilitation (Epithelial Physiology, Innsbruck Medical University).
Research Interests: Development of human-relevant in vitro models, systems toxicology, mitochondrial toxicity, xenobiotic metabolism, and translational biomarkers. His work emphasizes integrating omics data (transcriptomics, proteomics) with cheminformatics and computational models to predict chemical hazards.
Grants & Projects: Principal Investigator for RISKHUNT3R, CHIAZMA, VHP4SAFETY. Collaborates on EU initiatives like In3 (animal-free nanomaterial safety) and StemBANCC (stem cell-based drug toxicity).
Awards: None explicitly listed, though his leadership roles (Editor-in-Chief of Toxicology in Vitro, Vice President of NVT) highlight his professional standing.
Labs/Teams: Molecular and Computational Toxicology Division at VU, collaborating with international teams on projects like OpenRiskNet (e-infrastructure for risk assessment) and EUToxRisk (mechanism-based toxicity testing).
